Immuron LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

25 Sept 2025

IMRN

Immuron LTD

20-F: Immuron Reports Strong Sales Growth, Advances Pipeline

Immuron Limited's latest 20-F filing reveals significant revenue growth for its commercial products and progress in its clinical-stage drug candidates for infectious diseases.

NASDAQ

1 Oct 2024

IMRN

Immuron LTD

20-F: Immuron Limited Reports Financial Results for Fiscal Year 2024, Highlights Clinical Progress

Immuron Limited's fiscal year 2024 saw a significant increase in Travelan and Protectyn sales, alongside continued advancement of clinical programs targeting infectious diseases.